Jake Jorgovan

JANUARY 30, 2024

The Biopharma industry is always evolving. However, thought leaders in the Biopharma industry offer innovative insights and strategic direction. You're on the right page to find these experts; we’ll discuss Biopharma's top 12 thought leaders, highlighting their unique expertise and what they can teach you. Let’s dive in.

Biopharma 130

Biopharma Life science Biotech Biopharmaceuticals 130

Jake Jorgovan

NOVEMBER 15, 2023

If you’re in the BioPharma and Pharmaceutical industries, your most valuable resource isn’t just the latest breakthrough drug or cutting-edge technology. Enter the world of executive search firms, headhunters, and recruiters specializing in the BioPharma and Pharmaceutical industries. Let’s dive in.

Biopharma 130

Biopharma Life science Biotechnology Biotech 130

ISTO / IEEE

JANUARY 12, 2022

A group of leading BioPharma companies, academic institutions, and non-profit data-sharing platforms have come together to establish the Clinical Research Data Sharing Alliance (CRDSA). ISTO provides today’s industry alliances and trade associations with turnkey legal and operational support. PISCATAWAY, N.J., About ISTO.

Biopharma 113

Biopharma Legal Ecosystems Collaboration 113

Jake Jorgovan

NOVEMBER 15, 2023

With expertise in connecting organizations with top-tier executive talent, "Alliance International Services" is a trusted partner for businesses seeking CROs who can drive success in today's competitive landscape.

Life science 130

Life science Fintech Telecommunications Biopharma 130

Frost & Sullivan

APRIL 3, 2024

Simtra BioPharma Solutions announced over $250 million expansion of its sterile fill/finish manufacturing campus in Bloomington, Indiana. Growth Opportunity 2 – Medical Cannabidiol (CBD) Global regulatory shifts toward legalizing medical cannabis and CBD products highlight the growing interest in cannabis-based treatments.

Biopharmaceuticals 59

Biopharmaceuticals Biopharma Biotechnology Life science 59

LaVoie Health Science Blog

JULY 1, 2020

Given the number of public companies – including many blue-chip pharma and biopharma large caps – that have seen their stock prices swing wildly, from this strict valuation perspective alone, the current environment seems as if it should present a historic opportunity to activist investors. The current activism landscape, H1-2020.

Life science 52

Life science Biotech Biopharma Value creation 52